Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction

“Most of the randomized clinical trials supporting beneficial effects of beta-blockers in patients with AMI were conducted the era before routine use of reperfusion and revascularization therapy, antiplatelet drugs, statins, and renin-angiotensin-aldosterone system (RAAS) inhibitors. As these therapies have been proven to reduce the cardiovascular mortality of patients with AMI, whether beta-blockers continue to provide benefit has been in question. More recent trials establish a clear benefit of beta-blockers after AMI in patients with LVEF of 40% or below with or without heart failure symptoms.”